News

Pillar Biosciences is helping patients with cancer by making testing more accessible and efficient
Pillar Biosciences - Corporate Video - The Process

News

2025-09-05
Pillar Biosciences and Platomics Announce Collaboration to Support EU Clinical Labs with Documentation of NGS Workflows
2025-05-27
Pillar Biosciences Raises $34.5M in Funding
2025-02-18
Pillar Biosciences and Hamilton Company Announce NGS Application Development and Co-Marketing Agreement
2025-01-07
Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase
2024-10-16
Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina
2024-09-10
Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing
2024-04-26
Pillar Biosciences gets FDA approval for NGS solid tumor profiling test
2024-04-23
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™ Dx System
2023-11-10
Beckman Coulter Life Sciences and Pillar Biosciences announce NGS application development pipeline for the Biomek NGeniuS System
2023-07-25
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
2022-08-31
Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoRevealTM Dx Colon Cancer Assay
2022-07-31
Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx
2022-03-08
Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel
2022-01-06
Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory
2021-10-14
Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing
2021-10-13
Advancing Precision Oncology with Dr. Gang Song
2021-08-06
ORI Capital's Portfolio Company Pillar Receives FDA Premarket Approval for its oncoReveal(TM) Dx Lung and Colon Cancer Test
2020-10-14
Pillar Biosciences and PierianDx Announce Partnership to Support Precision Cancer Care
2020-10-06
Pillar Biosciences welcomes new independent board member Robert Forrester
2020-08-02
Pillar Biosciences appoints Dr. Eric Lai to its Board of Directors
2020-05-12
Pillar Biosciences Closes $29.7 Million in Series C Financing
2020-01-09
New 47-gene solid tumor panel from Pillar Biosciences now available for research use
2019-10-02
Meet SLIMamp: Columbia University’s new tumor sequencing workhorse
2019-03-23
Join Pillar Biosciences at the Association for Biomolecular Research Facilities Annual Meeting 2019
2019-01-01
Join Pillar at AMP 2019
2019-01-01
Custom Pillar NGS panel approved for clinical use at Columbia University Medical Center